Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder characterized by persistent airflow limitation that is not fully reversible. Clinically, COPD commonly manifests as chronic bronchitis and/or emphysema, with symptoms including chronic cough, sputum production, dyspnea, and reduced exercise tolerance. Pathophysiology involves chronic inflammation of the airways, structural remodeling, mucus hypersecretion, and destruction of alveolar attachments, often driven by smoking or exposure to inhalational irritants. While COPD is termed “incurable” in the sense that complete reversal of established structural damage is rarely possible, many patients achieve substantial symptom control and improved quality of life through evidence-based therapies.
The social-media claim prompting this discussion involves nebulized dimethyl sulfoxide (DMSO) in advanced or “terminal” COPD. DMSO is an organosulfur compound with well-described solvent and anti-inflammatory properties in laboratory settings. Proposed mechanisms for respiratory effects include modulation of oxidative stress, reduced leukocyte chemotaxis, altered cytokine signaling, and possible effects on epithelial permeability and mucus viscosity. In vitro and preclinical work has suggested that DMSO can scavenge free radicals and influence inflammatory pathways; however, translation to durable clinical benefit in COPD requires rigorous human trials demonstrating efficacy, dosing safety, and reproducibility.
From a clinical-evidence standpoint, COPD management relies on therapies with established benefit: smoking cessation, vaccinations, pulmonary rehabilitation, short- and long-acting bronchodilators, inhaled corticosteroids for selected phenotypes, and targeted treatments such as long-term oxygen for chronic hypoxemia and in some cases surgical or endobronchial interventions. These interventions improve exacerbation rates, reduce symptom burden, and can lower mortality risk for appropriate patient groups. By contrast, nebulized DMSO is not standard-of-care for COPD, and there is insufficient high-quality evidence to conclude that it “cures” COPD. Dramatic anecdotal improvements can occur for many reasons: resolution of a concurrent infection or bronchospasm, temporary reduction in airway inflammation, placebo effects, changes in medication adherence, differences in baseline severity, or improved supportive care.
Exacerbations are a major driver of short-term clinical changes in COPD. A patient labeled “terminal” may still experience exacerbation-related symptom variability, and bronchodilator responsiveness can be mistaken for disease reversal. Additionally, “asthma-like” features can overlap with COPD (asthma-COPD overlap), where bronchodilator and anti-inflammatory treatments can produce striking improvements. Without objective measures—spirometry (FEV1), lung volumes, diffusing capacity (DLCO), arterial blood gases, oxygen saturation trends, symptom scoring, and exacerbation history—claims of cure remain biologically implausible.
Safety considerations are crucial. DMSO’s pharmacology includes penetration into biological tissues and potential systemic absorption when used topically or via inhalation. Potential risks of inhaled DMSO include airway irritation, bronchospasm, cough, changes in mucociliary clearance, and unknown long-term toxicity from repeated nebulization. DMSO also has known risks in other contexts, including effects on skin and tissue, and interactions depending on formulation. Nebulized administration raises additional concerns: concentration, particle size distribution, stability of the solution, contamination, and variable dosing delivered to the lower airways.
If a patient is considering any non-standard inhaled therapy, clinicians should emphasize harm reduction: confirm COPD diagnosis, assess severity using guideline criteria, review current inhaler technique, ensure comorbidity optimization (cardiac disease, pulmonary hypertension, sleep-disordered breathing), and treat exacerbations promptly with evidence-based regimens. Patients should also be evaluated for alternative or coexisting diagnoses (e.g., asthma, bronchiectasis, interstitial lung disease) when symptoms appear atypical or rapidly responsive.
In summary, COPD is a chronic, multifactorial disease driven by persistent airway inflammation and structural lung changes. While DMSO has plausible anti-inflammatory properties and may influence oxidative pathways, credible clinical evidence for nebulized DMSO as a cure is lacking. Anecdotal recoveries can reflect variability in exacerbations, concurrent treatments, and unmeasured confounders. The safest, most effective approach remains guideline-concordant COPD care while encouraging patients to discuss experimental therapies with a pulmonologist and to demand rigorous clinical data for any proposed “curative” inhaled intervention. Source: @MidwesternDoc
A Midwestern Doctor: This is a recent update from the man with terminal COPD who was able to cure it with nebulized DMSO. He is mostly recovered now, his doctor admits he’s improved, and many others have also reported similar results for asthma, severe COPD, and other “incurable” lung disease.🧵. #breaking
— @MidwesternDoc May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
